Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology 30: Proteolytic Systems and Tumor Progression

Expression screening identifies a novel negative regulator (SM22/transgelin) of 92 kDa type IV collagenase expression

Rajesh R. Nair and Douglas D. Boyd
Rajesh R. Nair
M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas D. Boyd
M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

4344

Over expression of the 92-kDa type IV collagenase (MMP-9) contributes to the progression of several malignancies. However, to date, there are relatively few known regulators of expression of this metalloproteinase. We therefore employed an expression library comprised of 500,000 cDNA clones to screen for novel regulators of MMP-9 expression. Towards this end, HT1080 cells were transiently co-transfected with a MMP-9 promoter-luciferase reporter and pools of the cDNA expression library. Positive pools were subdivided in secondary and tertiary screens after which regulatory cDNAs were identified by DNA sequencing. Of several identified putative regulators, one cDNA was homologous to the calponin-related protein, SM22/transgelin. We were particularly intrigued with SM22 since its expression is down-regulated in several cancers known to overexpress MMP-9. Transient co-transfection of HT1080 cells with a SM22 expression vector and an MMP-9 promoter-driven luciferase reporter showed a dose-dependent decrease in luciferase expression. To determine the effect of SM22 on expression of the endogenous MMP-9 gene, HT1080 cells, which show high MMP-9 activity and low SM22 expression, were made to stably express SM22. HT-1080 cells, stably transfected with the SM22-GFP expression construct, demonstrated substantially lower MMP-9 enzymatic activity/mRNA as compared with the parental/empty vector cells. Further, PMA-induced MMP-9 expression was effectively countered by SM22 expression. Studies with 5’-deleted MMP-9 promoter fragments suggested that SM22 repressed MMP-9 expression at least in part through the AP-1 motifs present in the promoter. Moreover, nuclear extract from SM22-expressing cells showed reduced transcription factor binding to the MMP-9 promoter AP-1 motifs when compared with nuclear extract derived from empty vector-transfected cells. In conclusion, we have defined SM22 as a novel repressor of MMP-9 expression and determined that the repression is mediated, in part, via reduced AP-1 binding to the MMP-9 promoter.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Expression screening identifies a novel negative regulator (SM22/transgelin) of 92 kDa type IV collagenase expression
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Expression screening identifies a novel negative regulator (SM22/transgelin) of 92 kDa type IV collagenase expression
Rajesh R. Nair and Douglas D. Boyd
Cancer Res May 1 2005 (65) (9 Supplement) 1027;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Expression screening identifies a novel negative regulator (SM22/transgelin) of 92 kDa type IV collagenase expression
Rajesh R. Nair and Douglas D. Boyd
Cancer Res May 1 2005 (65) (9 Supplement) 1027;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inhibition of human prostate cancer growth and osteolysis in a bone metastasis model by a mechanism-based specific gelatinase inhibitor (SB-3CT)
  • TGF-beta-p38MAPK signaling contributes to tumor invasion and pulmonary metastases by increasing MMP9 activity and cell motility
  • Matrix Metalloproteinase-3/Stromelysin-1 expression by normal and tumorigenic keratinocytes enhances cell differentiation and reduces tumor establishment
Show more Tumor Biology 30: Proteolytic Systems and Tumor Progression
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement